Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats

Surgery

Volumn 143, Issue 3, 2008, Pages 375-383

  Liu, Keng Hao ^a   Liao, Li Min ^a   Ro, Long Sun ^a   Wu, Yu Lien ^a   Yeh, Ta Sen ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; FAS ANTIGEN; INITIATION FACTOR 4E; MESSENGER RNA; PROTEIN BAX; SODIUM CHLORIDE; THALIDOMIDE; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; BODY WEIGHT; CACHEXIA; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE TWITCH; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RIBONUCLEASE PROTECTION ASSAY; SKELETAL MUSCLE; SOLEUS MUSCLE; SPRAGUE DAWLEY RAT; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CACHEXIA; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; EUKARYOTIC INITIATION FACTOR-4E; IN SITU NICK-END LABELING; LIVER; MALE; MUSCLE FIBERS, FAST-TWITCH; MUSCLE, SKELETAL; RATS; RATS, SPRAGUE-DAWLEY; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 39149099965     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2007.09.035     Document Type: Article

References (34)

1. Khan A., Davidson B.R., Goldin R., et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51 Suppl VI (2002) vi1-vi9
2. Chen M.F., Jan Y.Y., Wang C.S., et al. Intrahepatic duct stone associated with cholangiocarcinoma. Am J Gastroenterol 84 (1989) 391-395
3. Chen T.C., Nakanuma Y., Yeh T.S., et al. Intraductal papillary ductal neoplasia of the liver associated with hepatolithiasis. Hepatology 34 (2001) 651-658
4. Yeh T.S., Tseng J.H., Chen T.C., et al. Characterization of intraductal growth type intrahepatic cholangiocarcinoma and its precursor. Hepatology 42 (2005) 657-664
5. Tisdate M.J. Protein loss in cancer cachexia. Science 289 (2000) 2293-2294
6. Guttridge D.C., Mayo M.W., Madrid L.V., et al. NF kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289 (2000) 2363-2366
7. Tisdale M.J. Cancer anorexia and cachexia. Nutrition 17 (2001) 438-442
8. Mreira A.L., Sampaio E.P., Zmuidzinas A., et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 177 (1993) 1675-1680
9. Ehrenpreis E.D., Kane S.V., and Cohen L.B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117 (1999) 1271-1277
10. Stevens R.J., Andujar C., Edwards C.J., et al. Thalidomide in the treatment of the cutaneous manifestation of lupus erythematous: experience in sixteen consecutive patients. Br J Rheumatol 36 (1997) 353-359
11. Sleijfer S., Kruit W.H.J., and Stoter G. Thalidomide in solid tumors: the resurrection of an old drug. EJC 40 (2004) 2377-2382
12. Eleutherakis-Papaiakovou V., Bamias A., and Dimopoulos M.A. Thalidomide in cancer medicine. Ann Oncol 15 (2004) 1151-1160
13. Minchinton A., Fryer K.H., Wendt K.R., et al. The effect of thalidomide on experimental tumors and metastasis. Anticancer Drugs 7 (1996) 339-343
14. Little R.F., Wyvill K.M., Pluda J.M., et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18 (2000) 2593-2602
15. Daliani D.D., Papandreou C.N., Thall P.F., et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95 (2001) 758-765
16. Baidas S.M., Winer E.P., Fleming G., et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. Br J Cancer 18 (2000) 2710-2717
17. Jan Y.Y., Yeh T.S., Yeh C.N., et al. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma. Appraisal of an animal model of cholangiocarcinoma. Ann Surg 240 (2004) 89-94
18. Ueno S., Aoki D., Kubo F., et al. Roxithromycin inhibits constitutive activation of nuclear factor kappaB by diminishing oxidative stress in a rat model of cholangiocarcinoma. Clin Cancer Res 11 (2005) 5645-5650
19. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 (1994) 4082-4085
20. Kevil C.G., Benedetti A.D., Payne D.K., et al. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 65 (1996) 785-790
21. Benedetti A.D., and Harris A.L. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 31 (1999) 59-72
22. Byrnes K., Hite S., Chu Q., et al. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 243 (2006) 684-692
23. Crew J.P., Fuggle S., Bicknell R., et al. Eukaryotic initiation factor 4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumor progression. B J Cancer 82 (2000) 161-166
24. V Polunovski I.B., Rosenwald A.T., Tan J., et al. Translational control of programmed cell death: eIF4 blocks apoptosis in growth factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 16 (1996) 6573-6581
25. Griffith T.S., Brunner T., Fletcher S.M., et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270 (1995) 1189-1192
26. Keane N.M., Ettenberg S.A., Lowrey G.A., et al. Fas expression and function in normal and malignant breast cell lines. Cancer Res 56 (1996) 4791-4798
27. Que F.G., Phan V.A., Celli A., et al. Cholangiocarcinoma express Fas ligand and disable the Fas receptor. Hepatology 30 (1999) 1398-1404
28. Shimonishi T., Isse K., Shibata F., et al. Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 32 (2000) 761-769
29. Khan Z.H., Simpson E.J., Cole T., et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 17 (2003) 677-682
30. Gordon J.N., Trebble T.M., Ellis R.D., et al. Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial. Gut 54 (2005) 540-545
31. Dubawitz V. Histological and biochemical stains and reactions. Muscle biopsy: a practical approach. 2nd ed. (1985), Ballière Tindal, London 19-40
32. Behan W.M.H., Cassar D.W., Madden H.A., et al. Validation of a simple, rapid, and economical technique for distinguishing type 1 and 2 fibers in fixed and frozen skeletal muscle. J Clin Pathol 55 (2002) 375-380
33. Chan R.K., Austen Jr. W.G., Ibrahim S., et al. Reperfusion injury to skeletal muscle affects primarily type II muscle fibers. J Surg Res 122 (2004) 54-60
34. Phillips T., and Leeuwenburgh C. Muscle fiber specific apoptosis and TNFα signaling in sarcopenia are attenuated by life-long caloric restriction. FASEB J 19 (2005) 668-670